Abstract
Atrial fibrillation (AF) and chronic heart failure (CHF) can be caused by each other, and therefore constitute a vicious circle. The prevalence of both conditions is about 1% in industrialized countries and increases with age. Although mortality is increased in heart failure, the additional prognostic relevance of AF in these patients is less clear. AF in patients with CHF can worsen heart failure symptoms, cause complications (eg, stroke), and is difficult to treat. Thus, prevention of AF entirely is an important goal. This review summarizes recent data concerning prognostic relevance, treatment, and means of primary and secondary prevention of AF in patients with CHF.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References Recommended Reading
Maisel WH, Stevenson LW: Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D–8D.
De Ferrari GM, Klersy C, Ferrero P, et al.: Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail 2007, 9:502–509.
Fujino T, Yamashita T, Suzuki S, et al.: Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J 2007, 71:936–940.
Li D, Fareh S, Leung TK, et al.: Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100:87–95.
Neuberger HR, Schotten U, Verheule S, et al.: Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005, 111:30–37.
Pai RG, Varadarajan P: Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 2007, 30:349–354.
Olsson LG, Swedberg K, Ducharme A, et al.: Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program. J Am Coll Cardiol 2006, 47:1997–2004.
Jahangir A, Lee V, Friedman PA, et al.: Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007, 115:3050–3056.
Swedberg K, Olsson LG, Charlesworth A, et al.: Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005, 26:1303–1308.
Corell P, Gustafsson F, Schou M, et al.: Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2007, 9:258–265.
Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833.
Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al.: Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the Rate Control versus Electrical cardioversion (RACE) study. Am Heart J 2005, 149:1106–1111.
Pedersen OD, Bagger H, Keller N, et al.: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001, 104:292–296.
Laufs U, Nef H, Mollmann H, et al.: Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association. Clin Res Cardiol 2008, 97:1–11.
Rienstra M, Van Gelder IC, van den Berg MP, et al.: A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. Int J Cardiol 2006, 109:95–100.
Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1–e82. [Published erratum appears in J Am Coll Cardiol 2006, 47:1503–1505.]
Fuster V, Ryden LE, Cannom DS, et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006, 8:651–745.
Swedberg K, Cleland J, Dargie H, et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26:1115–1140.
Khand AU, Rankin AC, Martin W, et al.: Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003, 42:1944–1951.
Van Veldhuisen DJ, Aass H, El Allaf D, et al.: Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006, 8:539–546.
Lechat P, Hulot JS, Escolano S, et al.: Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001, 103:1428–1433.
Chirinos JA, Castrellon A, Zambrano JP, et al.: Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm 2005, 2:525–529.
Hallberg P, Lindback J, Lindahl B, et al.: Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007, 63:959–971.
Gjesdal K, Feyzi J, Olsson SB: Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart 2008, 94:191–196.
Olshansky B, Rosenfeld LE, Warner AL, et al.: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201–1208.
Hofmann R, Steinwender C, Kammler J, et al.: Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol 2006, 110:27–32.
Ozcan C, Jahangir A, Friedman PA, et al.: Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001, 344:1043–1051.
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial [no authors listed]. JAMA 2002, 288:3115–3123.
Occhetta E, Bortnik M, Magnani A, et al.: Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol 2006, 47:1938–1945.
Brignole M, Gammage M, Puggioni E, et al.: Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J 2005, 26:712–722.
Doshi RN, Daoud EG, Fellows C, et al.: Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005, 16:1160–1165.
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999, 341:857–865.
Deedwania PC, Singh BN, Ellenbogen K, et al.: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998, 98:2574–2579.
van der Horst I, Voors AA, Van Veldhuisen DJ: Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 2007, 96:193–195.
Boldt LH, Rolf S, Huemer M, et al.: Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Am Heart J 2008, 155:890–895.
Boldt A, Scholl A, Garbade J, et al.: ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 2006, 101:261–267.
Salehian O, Healey J, Stambler B, et al.: Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007, 154:448–453.
Workman AJ, Kane KA, Russell JA, et al.: Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res 2003, 58:518–525.
Nasr IA, Bouzamondo A, Hulot JS, et al.: Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007, 28:457–462.
Hanna IR, Heeke B, Bush H, et al.: Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006, 3:881–886.
Adabag AS, Nelson DB, Bloomfield HE: Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007, 154:1140–1145.
Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al.: Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007, 74:75–84.
Adam O, Frost G, Custodis F, et al.: Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007, 50:359–367.
Hsu LF, Jais P, Sanders P, et al.: Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351:2373–2383.
Chen MS, Marrouche NF, Khaykin Y, et al.: Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004, 43:1004–1009.
Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al.: Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18:9–14.
Lutomsky BA, Rostock T, Koops A, et al.: Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging. Europace 2008, 10:593–599.
Grubitzsch H, Dushe S, Beholz S, et al.: Surgical ablation of atrial fibrillation in patients with congestive heart failure. J Card Fail 2007, 13:509–516.
Stulak JM, Dearani JA, Daly RC, et al.: Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 2006, 82:494–500.
Kindermann M, Hennen B, Jung J, et al.: Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol 2006, 47:1927–1937.
Gasparini M, Auricchio A, Regoli F, et al.: Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006, 48:734–743.
Gasparini M, Auricchio A, Metra M, et al.: Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008, 29:1644–1652.
Delnoy PP, Ottervanger JP, Luttikhuis HO, et al.: Comparison of usefulness of cardiac resynchronization therapy in patients with atrial fibrillation and heart failure versus patients with sinus rhythm and heart failure. Am J Cardiol 2007, 99:1252–1257.
Khadjooi K, Foley PW, Chalil S, et al.: Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart 2008, 94:879–883.
Hoppe UC, Casares JM, Eiskjaer H, et al.: Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006, 114:18–25.
Adelstein EC, Saba S: Burden of atrial fibrillation after cardiac resynchronization therapy. Am J Cardiol 2007, 100:268–272.
Hügl B, Bruns HJ, Unterberg-Buchwald C, et al.: Atrial fibrillation burden during the post-implant period after crt using device-based diagnostics. J Cardiovasc Electrophysiol 2006, 17:813–817.
Yannopoulos D, Lurie KG, Sakaguchi S, et al.: Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol 2007, 50:1246–1251.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Neuberger, HR., Reil, JC., Adam, O. et al. Atrial fibrillation in heart failure: Current treatment of patients with remodeled atria. Curr Heart Fail Rep 5, 219–225 (2008). https://doi.org/10.1007/s11897-008-0033-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11897-008-0033-x